| Literature DB >> 22859945 |
Grace W Irimu1, David Gathara, Dejan Zurovac, Harrison Kihara, Christopher Maina, Julius Mwangi, Dorothy Mbori-Ngacha, Jim Todd, Alexandra Greene, Mike English.
Abstract
BACKGROUND: Implementation of WHO case management guidelines for serious common childhood illnesses remains a challenge in hospitals in low-income countries. The impact of locally adapted clinical practice guidelines (CPGs) on the quality-of-care of patients in tertiary hospitals has rarely been evaluated. METHODS ANDEntities:
Mesh:
Year: 2012 PMID: 22859945 PMCID: PMC3409218 DOI: 10.1371/journal.pone.0039964
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Coverage of 5 day ETAT+ training among the front-line service providers in the paediatrics wards and Paediatric Emergency Unit (PEU).
Definition of the composite indicators of processes of care for each diseases.
| Domain of care | Criteria for considering the composite indicator achieved | Pneumonia | Dehydration | Severe malnutrition |
|
| Patient adequately assessed if all the following signs are assessed | Level of consciousness ability to drink | Level of consciousness, pulse character | Oedema, and weight for height Z-score or visual assessment of degree of severe wasting |
|
| Consistent with CPGs/ETAT+ if any the corresponding terms are used | Very severe pneumonia, severe pneumonia, | Shock, severe dehydration, some dehydration and no dehydration | Severe malnutrition, oedematous malnutrition, protein energy malnutrition, marasmic kwashiorkor, kwashiorkor marasmus |
|
| Consistent with CPGs if the following key treatment was prescribed at the correct dose and frequency (and duration for rehydration therapy) | Crystalline penicillin 50,000units/kg/dose X 4 per day (+/−20%) and/or Gentamicin 7.5 mg/kg/day X 1 per day (+/−20%) | Hartman's solution | 100–130 mls/kg/day (+/−20%) of F75 |
|
| Consistent with WHO/Kenya guidelines as adapted by the hospital staff | Evidence that doses of Crystalline penicillin were given as prescribed in the first 48 hrs of admission | Evidence that intravenous fluid (IV) therapy for severe dehydration was monitored | Evidence that intake of feeds for severe malnutrition was monitored |
Patients documented to have altered consciousness were assumed that they are not able to drink if ability to drink is not documented while patients documented in the history as able to drink were assumed to have the sign ‘able to drink’.
Patients documented as able to drink or alert were assumed not to have a weak pulse if pulse character was not documented.
was either a manufactured product (depending on the availability) or milk-based solution prepared in the hospital that provided 75kcal and 0.9g of protein/100 ml.
If dextrose added, correct if given at 2.4–6.0 mg/kg/min (approximates dextrose requirement for a sick child 3–5 mg/kg/min; +/−20%).
Initial treatment is considered given on time if it is given within 12 hours of admission on the ward.
Use of terms for severity of illness of the patients consistent with CPG/ETAT+ terms as recorded by clinicians on admission.
| Target disease | Illness classification | 2005 n (%) | 2006 n (%) | 2007 n (%) | 2008 n (%) | 2009 n (%) |
|
| ||||||
| Very severe pneumonia | 3/265 (1.1%) | 4/283 (1.3%) | 15/259 (5.8%) | 26/312 (8.3%) | 53/293 (18.1%) | |
| Severe pneumonia | 40/265 (15.1%) | 45/283 (15.0%) | 92/259 (35.5%) | 129/312 (41.4%) | 166/293 (56.7%) | |
| Not classified | 222/265 (83.8%) | 251/283 (83.7%) | 152/259 (58.7%) | 157/312 (50.3%) | 74/293 (25.3%) | |
|
| ||||||
| Shock | 0/296 (0%) | 5/308 (1.6%) | 13/303 (4.3%) | 8/334 (2.4%) | 25/294 (8.5%) | |
| Severe dehydration | 82/296 (27.6%) | 80/308 (26.0%) | 128/303 (42.2%) | 120/334 (36.0%) | 155/294 (52.7%) | |
| Some dehydration | 139/296 (46.8%) | 121/308 (39.3%) | 116/303 (38.3%) | 144/334 (43.4%) | 79/294 (26.9%) | |
| No dehydration | 1/296 (0.3%) | 4/308 (1.3%) | 9/303 (3.0%) | 26/334 (7.8%) | 7/294 (2.4%) | |
| Not classified | 75/296 (25.3%) | 98/308 (31.8%) | 37/303 (12.2%) | 35/334 (10.5%) | 28/294 (9.5%) | |
|
| ||||||
| Severe malnutrition | 216/274 (78.8%) | 172/223 (77.1%) | 194/246 (78.9%) | 135/179 (75.4%) | 160/197 (81.2%) | |
| Not classified | 58/274 (21.2%) | 51/223 (22.9%) | 52/246 (21.1%) | 44/179 (24.6%) | 37/197 (18.8%) | |
Not classified' means a diagnostic label captured by the target disease inclusion criteria but not consistent with ETAT+ terms was used.
Includes pneumonia, bronchopneumonia and lobar pneumonia.
Includes gastroenteritis and dehydration.
Includes severe malnutrition, marasmus, marasmic kwashiorkor, kwashiorkor, oedematous malnutrition and protein energy malnutrition.
Patients' characteristics (2005–2009) and comparison of characteristics between the pre-intervention (2005) and post-intervention periods (2009).
| Target disease | Patients characteristics | 2005 | 2006 | 2007 | 2008 | 2009 |
|
|
| |||||||
| Male n (% ) | 158/265 (59.6%) | 174/300 (58.0%) | 144/259 (55.6%) | 172/312 (55.1%) | 135/293 (46.1%) | 0.001 | |
| Median (IQR)age in months | 8 (4–14) | 8(5–14) | 8 (4–14) | 8 (5–15) | 7 (4–14) | 0.89 | |
| Median(IQR weight)in kilograms | 7.0 (5.5–9.0) | 7.1 (5.7–9.0) | 7.2 (6.1–8.7) | 7.1 | 7.0 (5.7–9.0) | 0.69 | |
| Median (IQR) duration of cough in days | 4 (3–7) | 4 (3–7) | 4 (3–7) | 4(3–7) | 4 (3–7) | 0.28 | |
|
| |||||||
| Male n (% ) | 156/297 (52.5%) | 182/308 (59.1%) | 165/303 (54.5%) | 194/334 (58.1%) | 139/294 (47.3%) | 0.200 | |
| Median age in months (IQR) | 7(5–11) | 8 (5–12) | 9(5–14) | 8(6–12) | 9(6–12) | 0.003 | |
| Median weight in kilogram (IQR) | 7.0 (5.9–8.1) | 7.2 (6.0–8.4) | 7.2 (6.2–8.5) | 7.3 (6.1–8.5) | 7.4 (6.3–8.6) | 0.004 | |
| Median duration (IQR) of diarrhoea in days | 4(3–6) | 3 (2–5) | 3 (2.5–5) | 3(3–5) | 3 (2–5) | 0.016 | |
|
| |||||||
| Male n (% ) | 130/274 (47.5%) | 117/223 (52.5%) | 124/246 (50.4%) | 79/179 (44.1%) | 82/197 (41.6%) | 0.21 | |
| Median (IQR) age in months | 14 (10–22) | 12 (9–18) | 12 (9–17) | 14 (9–20) | 13 (9–18) | 0.015 | |
| Median (IQR) weight in kilogram | 6.5 (5.5–8.0) | 6.0 (5.2–7.0) | 6.0 (5.1–7.0) | 6.0 (5.2–7.3) | 6.3 (5.3–7.3) | 0.056 | |
Chi square test.
Kruskal Wallis test.
Denominator does not include three patients with missing values.
Denominator does not include one patient with missing values.
Effects of the intervention on adequacy of assessment and illness classification.
| Domain of care | Composite and individual indicators | Patients who achieved the indicator in the pre-intervention period n (%,95% CI) | Patients who achieved the indicator in the post-intervention period n (%,95% CI) | Effect size – absolute difference in percentage %; (95% CI) |
|
|
| |||||
|
|
|
|
|
| |
| Level of consciousness | 58/265 (21.9%; 17.1–27.4) | 218/293 (74.4%; 69.0–79.3) | |||
| Ability to drink | 100/265 (37.7%; 31.9–43.9) | 155/293 (52.9; 47.0–58.7) | |||
| Cyanosis | 164/265 (61.9%; 55.7–67.8) | 220/293 (75.1%; 69.7–79.9) | |||
| Lower chest wall indrawing | 49/265 (18.5%; 14.0–23.7) | 238/293 (81.2%; 76.3–85.5) | |||
| Respiratory rate | 206/265 (77.7%; 72.2–82.6) | 255/293 (87.0%; 82.6–90.7) | |||
|
| |||||
|
|
|
|
|
| |
| Level of consciousness | 169/297 (56.9%; 51.1–62.6) | 247/294 (84.0%; 79.3–88.0) | |||
| Ability to drinkb | 88/297 (29.6%; 24.5–35.2) | 136/294 (46.3%; 40.5–52.1) | |||
| Pulse character | 74/297 (24.9%; 20.1–30.2) | 250/294 (85.0%; 80.4–88.9) | |||
| Sunken eyes | 86/297 (29.0%; 23.8–34.5) | 206/294 (70.1%; 64.5–75.2) | |||
| Skin turgor | 19/297 (6.4%; 3.9–9.8) | 211/294 (71.8%; 66.3–76.8) | |||
|
| |||||
|
|
|
|
|
| |
| Oedema | 193/274 (70.4%; 64.7–75.8) | 126/197 (64.0%; 56.8–70.7) | |||
| Visible severe wasting | 161/274 (58.8%; 52.7–64.7) | 103/197 (52.3%; 45.1–59.4) | |||
| Height | 0/274 (0%; N/A) | 51/197 (25.9%; 19.9–23.6) | |||
|
| |||||
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
|
| |
Effects of intervention on selected treatment practicesa.
| Composite and corresponding individual tasks indicators | Patients whose treatment was consistent with CPGs in the pre-intervention period n(%; 95% CI) | Patients whose treatment was consistent with CPGs in the post-intervention period n (%; 95% CI) | Effect size – difference in percentage % (95% CI) |
| |
|
|
|
|
|
|
|
| Patients who received less that 80% of the recommended dose of crystalline penicillin | 104/265 (39.2%, 33.3–45.4) | 6/287 (2.1%; 0.7–4.4) | |||
|
|
|
|
|
| |
| Frequency of gentamicin consistent with ETAT+ guidelines | 46/191 (24.1%; 18.2–30.8) | 138/140 (98.6%; 94.9–99.8) | |||
|
|
|
|
|
|
|
| Type of IVF consistent with CPGs | 219/265 (82.6%; 77.5–87.0) | 251/286 (87.8%; 83.4–91.3) | |||
| Volume of IVF consistent with CPGs | 160/265 (60.4%;54.2–66.3) | 205/286 (71.7%; 66.1–76.8) | |||
| Duration of IVF consistent with CPGs | 147/265 (55.5%; 49.3–61.6%) | 213/286 (74.5%; 69.0–79.4) | |||
|
|
|
|
|
|
|
| Patients with feeds prescribed | 233/274 (85.0%; 80.3–89.0) | 176/197(89.3%; 84.2–93.3) | |||
| Type of feed consistent with CPGs | 31/233 (13.3%; 9.2–18.4) | 142/176 (80.7%; 74.1–86.2) | |||
| Volume of consistent with CPGs | 124/233 (53.2%; 47.0–60.2) | 158/176 (89.8%; 84.3–93.8) | |||
Chi square test.
Composite indicator; achieved if dose and frequency of crystalline penicillin is consistent with CPGs.
Composite indicator; achieved if dose and frequency of gentamicin is consistent with CPGs.
Composite indicator; achieved if type, volume and duration of IVF is consistent with CPGs.
22 records for 2005 and 3 for 2009 were excluded in the analysis for treatment due to serum sodium >145 or <135 mmol/l. In addition 11 and 5 records in 2005 and 2009 respectively were excluded because there was no evidence that IVF was continued on the ward and diagnosis of either some dehydration or no dehydration was made.
Composite indicator; achieved if type and volume of feeds for severe malnutrition is consistent with CPGs.
Effect of intervention on the administration of the prescribed treatment in the first 48 hours of admission.
| Task in administration of treatment | Patients who had the task achieved in pre-intervention period n (%; 95% CI) | Patients who had the task achieved in post-intervention period. n (%; 95% CI) | effect size – difference in percentage % (95% CI) |
|
| Evidence that 8 doses crystalline was given for children with pneumonia | 20/154 (13.0%; 7.6–18.4) | 31 (16.6%; 11.2–22.0) | +3.6% (−3.9 to +11.1) | 0.36 |
| Median doses of crystalline penicillin (IQR) given for children with pneumonia | 5.5 (4.5–7.0) | 6.5 (5.5–7.5) | - | 0.54 |
| Intravenous fluid therapy for severe dehydration monitored | 2/285 (0.7%; 0.9–2.5) | 16/285 (5.6%; 3.2–9.0) | +4.9% (+2.1 to +7.8) | 0.001 |
| Patients with severe malnutrition that had feeds prescribed and whose feeds intake was documented in the feed chart | 3/223 (1.3%; −0.2 to 2.9) | 13/170 (7.6%; 3.6–11.7) | +6.3% (+2.0 to +10.6) | 0.002 |
Analysis restricted to patients alive after 2 days, crystalline penicillin prescribed as four times a day and not stopped during the first 2 days of admission.
Chi square test.
Kruskal Wallis test.
Analysis restricted to patients with evidence that intravenous fluid (IVF) was prescribed on the ward and were alive after one day of admission.
Analysis restricted to patients who had feed prescribed and were alive after 1 day of admission.
Effect of intervention on review of patients who died in the first 48 hours of admission.
| Composite indicator | Individual task | Patients who had the task/indicator achieved in the pre-intervention period n (%; 95% CI) | Patients who had the task/indicator achieved in the post-intervention period n (%; 95% CI) | effect size – difference in percentage % (95% CI) |
|
| Nurses' review and documentation of vital signs | 6houly review of vital signs | 1/93 (1.1%; 0.0 to −5.8) | 3/45 (6.7%; 1.4–18.2) | +5.6% (−2.0 to +13.2) | 0.066 |
| Temperature | 1/93 (1.1%; 0.0 to −5.8) | 3/45 (6.7%; 1.4–18.2) | |||
| Respiratory rate | 1/93 (1.1%; 0.0 to −5.8) | 3/45 (6.7%; 1.4–18.2) | |||
| Pulse rate | 1/93 (1.1%; 0.0 to −5.8) | 3/45 (6.7%; 1.4–18.2) | |||
| Clinicians' review | Review of the critically sick patients 12hrly | 4/93 (4.3%; 1.2–10.6) | 2/45 (4.4%; 0.5–15.1) | 0.1% (−7.2 to +7.4) | 0.96 |
| Clinicians review 6hrs before death | 21/93 (22.6%; 14.6–32.4) | 17/45 (37.8%; 23.8–53.5) |
Analysis restricted to patients who died within 5 days of admission but were alive on the first day of admission.
All the three vital signs (temperature, pulse and respiratory rate) assessed.
Chi square test.
Test for trend of performance of the composite indicators for each target disease across the periods.
| Target disease | Composite indicator | Period 0 Proportion (%, 95% CI) | Period 1 Proportion (%, 95% CI) | Period 2 Proportion (%, 95% CI) | Period 3 Proportion (%, 95% CI) | P-value of chi squared for trend |
|
| ||||||
| Adequately assessed | 5/265 (1.9%; 0.6–4.3%) | 5/300 (1.7%; 0.5–3.8%) | 62/403 (15.4%;12.0–19.2%) | 107/461 (23.2%;19.4–27.3%) | <0.001 | |
| correctly classified | 43/265 (16.2%; 12.0–21.2%) | 49/300 (16.3%;12.3–21.0) | 178/403 (44.2%; 39.3–49.1%) | 303/461 (65.7%; 61.2–70.1%) | <0.001 | |
| Dose of crystalline penicillin consistent with CPGs | 137/265 (51.7%; 45.5–57.9%) | 209/300 (69.7%; 64.1–74.8%) | 343/399 (86.0%; 82.2–89.2) | 409/452 (90.5%; 87.4–93.0%) | <0.001 | |
| Dose of gentamicin consistent with CPGs | 38/191(19.9%;14.5–26.3%) | 167/243(68.7%; 62.5–74.5%) | 175/242 (72.3%; 66.2–77.9%) | 221/244 (90.6%; 86.2–93.9%) | <0.001 | |
| Administration of crystalline penicillin | 20/154 (13.0%; 8.1–19.3%) | 20/163 (12.3%; 7.7–18.3%) | 19/216 (8.8%; 5.4–13.4%) | 43/275 (15.6%; 11.6–20.5%) | 0.463 | |
|
| ||||||
| Adequately assessed | 0/297 | 1/308 (0.3%; 0.0–1.8%) | 45/490 (9.2%; 6.8–12.1%) | 108/441 (24.5%;20.5–28.9% | <0.001 | |
| correctly classified | 222/297 (74.5%; 69.4–79.6%) | 210/308 (68.2%; 62.7–73.3%) | 429/490 (87.5%; 84.3–90.3%) | 402/441 (91.2; 88.1–93.6%) | <0.001 | |
| IVF therapy consistent with CPGs | 100/265 (37.5%; 31.9–43.9%) | 118/290 (40.7%; 35.0–46.6%) | 249/473 (52.6%; 48.0–57.2%) | 260/422 (61.2%; 56.8–66.3%) | <0.001 | |
| IVF monitored | 2/297 (0.1%; 0.1–2.4%) | 1/308 (0.3%; 0.0–1.8%) | 7/490 (1.4%; 0.58–2.92%) | 18/441 (4.1%; 2.4–6.4%) | <0.001 | |
|
| ||||||
| Adequately assessed | 120/274 (43.8; 37.8–49.9%) | 93/223 (41.7; 39.2–48.5%) | 125/335 (37.3; 32.1–42.7%) | 114/287 (39.7; 34.0–45.6%) | 0.20 | |
| correctly classified | 216/274 (78.8; 73.5–83.5%) | 172/223 (77.1; 71.1–82.5%) | 264/335 (78.8%; 74.0–83.1%) | 225/287 (78.4%; 73.2–83.0%) | 0.98 | |
| Feeds therapy consistent with CPGs | 25/274 (9.1; 0.6–13.2%) | 108/223 (48.4; 41.7–55.2%) | 185/335 (55.2; 49.7–60.6%) | 209/287 (72.8; 67.2–77.9%) | <0.001 | |
| Feeds monitored | 3/223 (1.3; 0.2–3.9%) | 1/198 (0.5%; 0–2.7%) | 13/271 (4.8%; 2.6–8.1%) | 20/247 (8.1%; 5.0–12.2%) | <0.001 | |